# A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants

> **NCT03710486** · — · COMPLETED · sponsor: **Takeda** · enrollment: 409 (actual)

## Conditions studied

- Colitis, Ulcerative
- Crohn Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03710486
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-19
- **Primary completion:** 2021-08-23
- **Final completion:** 2022-02-21
- **Target enrollment:** 409 (ACTUAL)
- **Last updated:** 2024-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03710486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03710486, "A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03710486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*